Autochthonic Mediterranean spotted fever in West Germany.

Erythromycin versus tetracycline for treatment of Mediterranean spotted fever. Arch Dis Child (1986) 1.19

Randomized double-blind evaluation of ciprofloxacin and doxycycline for Mediterranean spotted fever. Antimicrob Agents Chemother (1989) 1.09

A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother (1998) 5.64

Prevalence of antibodies to human herpesviruses and hepatitis B virus in patients at different stages of human immunodeficiency virus (HIV) infection. Infection (1991) 3.29

Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet (2003) 3.23

HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA (2001) 2.95

Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS (1997) 2.59

Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. Atherosclerosis (2007) 2.16

Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS (2000) 2.15

A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. Antimicrob Agents Chemother (1999) 2.08

In vitro activity of HR 756, a new cephalosporin compound. J Antibiot (Tokyo) (1978) 1.98

Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. JAMA (1996) 1.94

Isolation frequency and growth properties of HIV-variants: multiple simultaneous variants in a patient demonstrated by molecular cloning. J Med Virol (1987) 1.92

[Clinic and diagnosis of enteric infections in man by Yersinia enterocolitica (author's transl)]. Infection (1973) 1.90

Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS (2001) 1.75

Demonstration of the Th1 to Th2 cytokine shift during the course of HIV-1 infection using cytoplasmic cytokine detection on single cell level by flow cytometry. AIDS (1997) 1.57

[Syrian hamsters as vectors of lymphocytic choriomeningitis]. Dtsch Med Wochenschr (1972) 1.56

Kaposi's sarcoma in HIV infection: impact on opportunistic infections and survival. AIDS (1998) 1.51

An infectious disease transmitted by Cercopithecus aethiops. ("Green monkey disease"). Ger Med Mon (1968) 1.47

A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy. J Infect Dis (1999) 1.46

Sex hormones as a cofactor in the pathogenesis of epidemic Kaposi's sarcoma. AIDS (1995) 1.43

Bioelectrical impedance analysis as a predictor of survival in patients with human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.38

Multiple sclerosis and Chlamydia pneumoniae. Ann Neurol (2000) 1.37

[Clinical experience with a new cephalosporin derivative, Cefotaxim]. Med Welt (1979) 1.33

Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group. J Infect Dis (2004) 1.31

HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy. AIDS (2000) 1.29

Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther (2004) 1.28

Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure. J Infect Dis (1998) 1.26

In vitro activity of norfloxacin in urine compared to that of cinnoxacin, nalidixic acid and pipemidic acid. Eur J Clin Microbiol (1983) 1.26

Isolation of variants of lymphocytopathic retroviruses from the peripheral blood and cerebrospinal fluid of patients with ARC or AIDS. J Med Virol (1986) 1.26

Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS (2000) 1.23

Restricted IgG subclass responses to HTLV-III/LAV and to cytomegalovirus in patients with AIDS and lymphadenopathy syndrome. J Infect Dis (1986) 1.22

4-quinolones inhibit biotransformation of caffeine. Eur J Clin Pharmacol (1988) 1.14

Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride. Antimicrob Agents Chemother (1998) 1.12

The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors. AIDS (1998) 1.11

Escherichia coli and Klebsiella pneumoniae strains more susceptible to cefoxitin than to third generation cephalosporins. J Antimicrob Chemother (1983) 1.10

Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: the Frankfurt HIV-cohort study. Eur J Med Res (2000) 1.10

Effect of aminoglycosides on proximal tubular membranes of the human kidney. Eur J Clin Pharmacol (1978) 1.09

Virological response to protease inhibitor therapy in an HIV clinic cohort. AIDS (1999) 1.09

Clinical experience with cefotaxime in internal medicine between 1981 and 1984. Drugs (1988) 1.07

Fluconazole prophylaxis of recurrent oral candidiasis in HIV-positive patients. Eur J Clin Microbiol Infect Dis (1991) 1.06

Activity of amikacin at sub-inhibitory levels. J Antimicrob Chemother (1976) 1.03

[Paradoxic bactericidal effect of penicillins on enterococci (Eagle effect)]. Dtsch Med Wochenschr (1973) 1.03

The virological response to highly active antiretroviral therapy over the first 24 weeks of therapy according to the pre-therapy viral load and the weeks 4-8 viral load. AIDS (2001) 1.02

HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohort. Antivir Ther (2000) 1.01

Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals. AIDS (2001) 0.99

The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load. AIDS (2000) 0.99

Changing incidence and survival in patients with aids-related non-Hodgkin's lymphomas in the era of highly active antiretroviral therapy (HAART). Leuk Lymphoma (2001) 0.98

Rebound of HIV-1 viral load after suppression to very low levels. AIDS (1998) 0.97

[Bactericidal dosie-activity relationships with E. coli, K. pneumoniae and Staph. aureus (author's transl)]. Dtsch Med Wochenschr (1976) 0.96

First case of successful allogeneic stem cell transplantation in an HIV-patient who acquired severe aplastic anemia. Haematologica (2007) 0.96

Early changes of body composition in human immunodeficiency virus-infected patients: tetrapolar body impedance analysis indicates significant malnutrition. Am J Clin Nutr (1993) 0.95

[Therapy of systemic mycoses in immunodeficiency]. Immun Infekt (1991) 0.94

Clinical experience with non-nucleoside reverse transcriptase inhibitors. AIDS (1997) 0.94

Ex vivo induction of apoptosis in lymphocytes is mediated by oxidative stress: role for lymphocyte loss in HIV infection. Free Radic Biol Med (1997) 0.93

HIV-2 (West Germany, 1984) Lancet (1987) 0.93

Factors associated with viral rebound among highly treatment-experienced HIV-positive patients who have achieved viral suppression. HIV Med (2008) 0.93

Efficacy of antibiotics in bacteriobilia. J Antimicrob Chemother (1982) 0.92

Resistance profiles in patients with viral rebound on potent antiretroviral therapy. J Infect Dis (2000) 0.92

Fluconazole in the treatment of oropharyngeal candidosis in HIV-positive patients. Mycoses (1991) 0.92

Kaposi's sarcoma in HIV infected women in Germany: more evidence for sexual transmission. A report of 10 cases and review of the literature. Genitourin Med (1994) 0.91

Treatment during primary HIV infection does not lower viral set point but improves CD4 lymphocytes in an observational cohort. Eur J Med Res (2009) 0.91

CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load. J Infect Dis (1999) 0.91

Intensification of a failing regimen with zidovudine may cause sustained virologic suppression in the presence of resensitising mutations including K65R. J Infect (2010) 0.90

Alternating treatment of common bile duct stones with a modified glyceryl-1-monooctanoate preparation and a bile acid-EDTA solution by nasobiliary tube. Scand J Gastroenterol (1981) 0.87

Itraconazole for prophylaxis of systemic mycoses in neutropenic patients with haematological malignancies. J Antimicrob Chemother (1996) 0.87

Risk of new AIDS diseases in people on triple therapy. Lancet (1999) 0.87

[Oyster-transmitted hepatitis]. Dtsch Med Wochenschr (1972) 0.87

The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS-related complex: a double-blind randomized trial. European-Australian Collaborative Group. AIDS (1993) 0.86

Turnover of circulating virion RNA and of cell-associated viral DNA reflects active viral replication in human immunodeficiency virus type 1-infected individuals. J Virol (1995) 0.86

[On an infectious disease transmitted by Cercopithecus aethiops. ("Green monkey disease")]. Dtsch Med Wochenschr (1968) 0.86

Effect of concentration on bactericidal activity of cefotaxime. J Antimicrob Chemother (1979) 0.86

Treatment of AIDS-related Kaposi's sarcoma with recombinant gamma-interferon. Onkologie (1986) 0.85

[Itraconazole suspension in the treatment of HIV-infected patients with fluconazole-resistant oropharyngeal candidiasis and esophagitis]. Mycoses (1996) 0.85

Treatment of diarrhoea in human immunodeficiency virus-infected patients with immunoglobulins from bovine colostrum. Clin Investig (1992) 0.85

Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA. J Clin Invest (2000) 0.84

[Intestinal permeability in patients with acquired immunodeficiency syndrome (AIDS)]. Klin Wochenschr (1991) 0.84

Treatment of oral 'hairy' leukoplakia in AIDS patients with vitamin A acid (topically) or acyclovir (systemically) Dermatologica (1987) 0.84

Increase in Vdelta1+ gammadelta T cells in the peripheral blood and bone marrow as a selective feature of HIV-1 but not other virus infections. Br J Haematol (1998) 0.84

[Pathogen elimination after surgical interventions on common bile duct (author's transl)]. Langenbecks Arch Chir (1979) 0.84

A dose comparison study of didanosine in patients with very advanced HIV infection who are intolerant to or clinically deteriorate on zidovudine. German ddI Trial Group. AIDS (1995) 0.84

[Spontaneous course of LAV/HTLV-III infection. Follow-up of persons from AIDS-risk groups]. Dtsch Med Wochenschr (1986) 0.83

[Shunt sepsis. On the clinical aspects of septic complications of intermittent hemodialysis]. Dtsch Med Wochenschr (1967) 0.83

HIV transmission from male after only two sexual contacts. Lancet (1987) 0.83

[In vitro studies on intermittent therapy with penicillin G and ampicillin]. Med Welt (1978) 0.83

Interventional antimicrobial therapy in febrile neutropenic patients. Study Group of the Paul Ehrlich Society for Chemotherapy. Ann Hematol (1994) 0.83

Human immunodeficiency virus type-1 group M quasispecies evolution: diversity and divergence in patients co-infected with active tuberculosis. Med Microbiol Immunol (2010) 0.82